Neumora submits IND for NMRA-215, reports dose data for NMRA-511
Neumora reported third-quarter 2026 results alongside an FDA IND submission for its NLRP3 inhibitor and new multiple ascending dose data for its vasopressin 1a receptor antagonist.
Neumora Therapeutics announced on November 16, 2026 that it had submitted an Investigational New Drug application to the FDA for NMRA-215, a potentially best-in-class, highly brain-penetrant oral NLRP3 inhibitor being developed for obesity and cardiometabolic disease.1 The company also presented preclinical results from NMRA-215 at ObesityWeek 2026, showing diet-induced obesity mouse studies in which the compound produced weight loss of up to 19% as a monotherapy and up to 26% in combination with semaglutide.1
For NMRA-511, a vasopressin 1a receptor antagonist, Neumora reported results from a multiple ascending dose expansion cohort evaluating a 30 mg BID dose in healthy elderly participants.1 That dose showed a favorable safety and tolerability profile with no serious adverse events, and dose-proportional increases in exposure compared to the 20 mg BID dose used in the earlier Phase 1b study.1 The company said the 30 mg BID dose may build on the efficacy seen with the 20 mg BID dose in Phase 1b, and noted the program is Phase 2 enabled.1 Separately, the Phase 1 multiple ascending dose study of NMRA-898, an M4 positive allosteric modulator, in healthy volunteers and patients with stable schizophrenia, is ongoing.1
On financials, Neumora reported cash and cash equivalents of $85.7 million as of September 30, 2026.1 The company said it is not providing updated financial runway guidance, noting in its Form 10-Q that it will require substantial additional funding to continue operations and complete development and potential commercialization of its product candidates, with no assurance such funding will be available on acceptable terms or at all.1 Neumora reported a net loss of $34.4 million for the third quarter of 2026, compared with $56.8 million for the same period in 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.